SUSEN, Sophie; GRUEL, Yves; GODIER, Anne; HARROCHE, Annie; CHAMBOST, Herve; LASNE, Dominique; RAUCH, Antoine; ROULLET, Stéphanie; FONTANA, Pierre; GOUDEMAND, Jenny; DE MAISTRE, Emmanuel; CHAMOUARD, Valerie; WIBAUT, Bénédicte; ALBALADEJO, Pierre; NÉGRIER, Claude

doi:10.1111/hae.13817

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Haemophilia. 2019-09, vol. 25, n° 5, p. 731–737

Résumé en anglais

INTRODUCTION: Emicizumab (Hemlibra® ) recently became available and requires an adaptation for managing bleeding, suspected bleeding and emergency or scheduled invasive procedures in haemophilia A patients with inhibitor. This implicates a multidisciplinary approach and redaction of recommendations for care that must be regularly adapted to the available data. AIM: The following text aims to provide a guide for the management of people with haemophilia A with inhibitor treated with emicizumab in case of bleeding or invasives procedures. METHODS: The French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia (CRH), in collaboration with the French Working Group on Perioperative Haemostasis (GIHP) have been working together to make proposals for the management of these situations. RESULTS: Haemostatic treatment and other medications should be given stepwise, according to the severity and location of the bleeding or the risk of bleeding of the procedure as well as the haemostatic response obtained at each step in order to ensure an optimal benefit/risk ratio. CONCLUSION: The lack of data means that it is only possible to issue proposals rather than recommendations.< Réduire

Mots clés

Article CLINIQUE